{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most prevalent known cause of autosomal dominant Parkinson's disease (PD). The Y1699C mutation in the COR domain is linked to reduced GTPase activity and altered dimerization, contributing to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism for LRRK2 mutations, including Y1699C, as related to altered GTPase activity and dimerization properties, which are critical to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses GTPase activity assays and protein interaction assays (e.g., yeast two-hybrid, GST pulldown, co-immunoprecipitation) to assess the impact of Y1699C on LRRK2 function, reflecting disease mechanisms of PD through catalytic core interactions and GTPase activity.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (GTPase activity and protein interaction assays) are appropriate and widely used in the field to model the disease mechanism of PD related to LRRK2 dysfunction.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 and dysfunctional mutants (e.g., T1348N) were used as controls in GTPase assays (Fig. 1B). Experiments were confirmed in two independent experiments with results depicted as change in absorbance over time (n=3 for GTPase activity).",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type) and abnormal (T1348N dysfunctional mutant) controls were included. Replicates are explicitly mentioned (n=3 for GTPase assays and two independent experiments), satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic mutants such as R1441C were used alongside Y1699C in GTPase activity and dimerization assays (Fig. 1B, Fig. 2). These mutants are established as pathogenic in PD literature.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (e.g., R1441C) were used as controls in the assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance for GTPase activity and interaction assays was determined using Mann-Whitney U test and Student's t-test (p<0.05). Quantitative data for GTPase activity (Fig. 1B) and interaction strength (Fig. 4C) are provided with error bars (n=3-6), but no direct OddsPath calculation is reported.",
          "judgment": "No",
          "reasoning": "While statistical analyses are present (p-values and error bars), there is no direct calculation or estimation of OddsPath for pathogenicity likelihood based on functional data for Y1699C.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation - Count of Benign/Pathogenic Controls",
          "extracted_paper_info": "The study includes multiple pathogenic controls such as R1441C, R1441G, R1441H, and Y1699C itself, along with dysfunctional mutants like T1348N and K1347A across assays (Fig. 1B, Fig. 2). Total pathogenic controls exceed 4, but no benign controls are explicitly mentioned.",
          "judgment": "Less than 11 total controls",
          "reasoning": "Although several pathogenic controls are used (at least 4 distinct mutants), the total number of unique benign and pathogenic variant controls does not reach 11, and no benign controls are explicitly identified in the assays related to Y1699C.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 Y1699C is rated as PS3_supporting due to the clear demonstration of reduced GTPase activity and altered dimerization consistent with pathogenicity in PD. The assays used are appropriate and include basic and variant controls, but the lack of OddsPath calculation and insufficient total number of benign/pathogenic controls limits the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2, including R1441C in the ROC domain, are linked to autosomal dominant Parkinson's disease (PD) through reduced GTPase activity and altered dimerization properties.",
          "judgment": "Yes",
          "reasoning": "The paper clearly outlines the disease mechanism for LRRK2 mutations like R1441C, associating them with PD via impacts on GTPase activity and protein interactions."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "GTPase activity assays and protein interaction assays (e.g., yeast two-hybrid, GST pulldown) were used to evaluate R1441C's impact on LRRK2 function, mirroring PD pathogenesis mechanisms.",
          "judgment": "Yes",
          "reasoning": "The assays employed are standard in the field for assessing LRRK2-related PD mechanisms, focusing on GTPase activity and dimerization.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 and dysfunctional mutants (e.g., T1348N) served as controls in GTPase assays (Fig. 1B). GTPase activity was confirmed in two independent experiments with n=3 replicates.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type) and abnormal (T1348N) controls are included, and replicates are explicitly mentioned (n=3, two independent experiments), meeting the criteria.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic mutants such as Y1699C were used alongside R1441C in GTPase activity and dimerization assays (Fig. 1B, Fig. 2), with established pathogenic status in PD.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (e.g., Y1699C) were used as controls, satisfying the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was assessed using Mann-Whitney U test and Student's t-test (p<0.05). Quantitative data for GTPase activity (Fig. 1B) and dimerization (Fig. 2) include error bars (n=3-4), but no OddsPath is calculated or inferred.",
          "judgment": "No",
          "reasoning": "Statistical analyses are present, but there is no direct or inferred OddsPath calculation for R1441C based on functional data.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation - Count of Benign/Pathogenic Controls",
          "extracted_paper_info": "Pathogenic controls include R1441C, R1441G, R1441H, Y1699C, and dysfunctional mutants T1348N and K1347A (Fig. 1B, Fig. 2). Total pathogenic controls are at least 4, but no benign controls are mentioned.",
          "judgment": "Less than 11 total controls",
          "reasoning": "The total number of unique benign and pathogenic variant controls is below 11, with no benign controls explicitly identified in the assays for R1441C.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1441C is rated as PS3_supporting due to demonstrated reduction in GTPase activity and weakened dimerization, aligning with pathogenicity in PD. Appropriate assays with controls are used, but the absence of OddsPath calculation and limited control variant count restricts the strength to supporting."
    }
  ]
}